Clinical Trial Update: PDL-1 Targeting in Resectable Oesophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating PD-L1 targeting in resectable esophageal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Esophageal Cancer, Stage II, Esophageal Cancer Stage III | Phase 2 | Status: COMPLETED